Advances in Predictive Biomarkers for Immune Checkpoint Inhibitors in Lung Cancer: Why, Who, and How

Join us for this interactive, CME/MOC-certified symposium featuring insights from medical oncology and pathology experts on the latest data informing optimal implementation of immunotherapy biomarkers into the management of patients with lung cancer.


6:30 PM  Registration and Dinner

7:00 PM  Program Overview
Hossein Borghaei, MS, DO

7:05 PM  The How: Current Predictors of Response to Immune Checkpoint Inhibitors
Sanjay Mukhopadhyay, MD

7:30 PM   The Why and Who: Overview of Immune Checkpoint Blockade in Lung Cancer
Joshua Bauml, MD

7:55 PM  The Future: Opportunities for Predictive Biomarkers in Cancer Immunotherapy
Hossein Borghaei, MS, DO

8:20 PM  Panel Discussion and Audience Q&A Session


Date / Time
Event Details


Program Chair
Hossein Borghaei, DO

Professor and Chief, Thoracic Oncology
The Gloria and Edmund M. Dunn Chair in Thoracic Oncology
Department of Hematology and Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Joshua Bauml, MD

Assistant Professor of Medicine 
Division of Hematology/Oncology
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Sanjay Mukhopadhyay, MD

Director, Pulmonary Pathology
Department of Pathology
Cleveland Clinic
Cleveland, Ohio

Goal Statement
The goal of this activity is to improve participants’ knowledge of and competence in assessing biomarkers to guide the use of immune checkpoint inhibitors in the treatment of patients with lung cancer.

Target Audience
This program is intended for pathologists and other healthcare providers who treat and manage patients with lung cancer.

Learning Objectives

  • Evaluate the clinical utility of predictive biomarkers for immune checkpoint inhibitor response in lung cancer by line of therapy, available therapeutic alternatives, and health economic considerations
  • Compare and contrast the different methodologies and assays for identifying biomarkers of response to immune checkpoint inhibitors in different lung cancer histologies and treatment settings
  • Implement best practices for biomarker testing/interpretation of results to guide treatment selection in different lung cancer histologies and treatment settings
  • Summarize ongoing research regarding the utility of biomarkers, PD-L1, MSI/MMR, tumor mutational burden, DNA damage repair, T-cell functional state, composite biomarkers, or other host factors predictive of response to and/or toxicities associated with immune checkpoint inhibitors


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Pathology Continuing Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Lifelong Learning (Part II) and Self-Assessment Module (SAM) points in the American Board of Pathology's Maintenance of Certification (MOC) Program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.

If you are interested in having us report ABPath MOC, please ensure the following information is provided within your Member Profile:

Name - as registered with ABPath
Date of Birth (Month/Day)
Your ABPath ID number

Learners must complete the post-test with a passing score of 75% and provide additional documentation following the symposium. 

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.